Associated Papers
Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer.
Siegel F et al.
Cancer Discovery, 2026
41090369 (PubMed )
Supplement: cd-25-0605_figure_s3_suppsf3.pdf
Molecular and immunohistochemical characterization of ERBB2 activating mutations in low-grade serous ovarian carcinoma.
Neil AJ et al.
Histopathology, 2025
Diverse ERBB2/ERBB3 Activating Alterations and Coalterations Have Implications for HER2/3-Targeted Therapies across Solid Tumors.
Liu D et al.
Cancer Research Communications, 2025
40178042 (PubMed )
Supplement: crc-24-0620_supplementary_figure_s3_suppsf3.pdf
Real-World Prevalence, Treatment Patterns, and Outcomes for Patients With HER2 (ERBB2)-Mutant Metastatic Non-Small Cell Lung Cancer, From a US-Based Clinico-Genomic Database.
Waliany S et al.
Cancer Medicine, 2024
Molecular landscape of ERBB2 alterations in 3000 advanced NSCLC patients.
Hong L et al.
Npj Precision Oncology, 2024
Clinical and structural insights into the rare but oncogenic HER2-activating missense mutations in non-small cell lung cancer: a retrospective ATLAS cohort study.
Yang G et al.
Discover Oncology, 2024
Genomic and immune characteristics of HER2-mutated non-small-cell lung cancer and response to immune checkpoint inhibitor-based therapy.
Tu HY et al.
Molecular Oncology, 2023
ERBB family fusions are recurrent and actionable oncogenic targets across cancer types.
Schubert L et al.
Frontiers in Oncology, 2023
37168365 (PubMed )
Supplement: Table_3.xlsx › ERBB2_mutations
Pyrotinib in HER2 heterogeneously mutated or amplified advanced non-small cell lung cancer patients: a retrospective real-world study (PEARL).
Yang G et al.
Journal of the National Cancer Center, 2021
Targeting HER2 genomic alterations in non-small cell lung cancer.
Zeng J et al.
Journal of the National Cancer Center, 2021
Non-small-cell lung cancer with ERBB2 mutation in non-tyrosine kinase domain benefits from pyrotinib: A case report.
Ni J et al.
Thoracic Cancer, 2021
Mutational landscape and characteristics of ERBB2 in non-small cell lung cancer.
Wei XW et al.
Thoracic Cancer, 2020
The HER2 S310F Mutant Can Form an Active Heterodimer with the EGFR, Which Can Be Inhibited by Cetuximab but Not by Trastuzumab as well as Pertuzumab.
Shin JW et al.
Biomolecules, 2019
Genomic heterogeneity of multiple synchronous lung cancer.
Liu Y et al.
Nature Communications, 2016
27767028 (PubMed )
Supplement: ncomms13200-s1.pdf
Analysis of different HER-2 mutations in breast cancer progression and drug resistance.
Sun Z et al.
Journal of Cellular and Molecular Medicine, 2015
Oncogenic RIT1 mutations in lung adenocarcinoma.
Berger AH et al.
Oncogene, 2014
24469055 (PubMed )
Supplement: 41388_2014_BFonc2013581_MOESM17_ESM.xls › Supplementary_Table_5
Activating Mutations in ERBB2 and Their Impact on Diagnostics and Treatment.
Herter-Sprie GS et al.
Frontiers in Oncology, 2013
Select a paper to view details